STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co., Inc. - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.

Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.

Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.

The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.

From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.

News

Merck to Participate in the Barclays 26th Annual Global Healthcare Conference

Rhea-AI Summary
Merck (MRK) announces Jannie Oosthuizen's participation in fireside chat at Barclays Global Healthcare Conference. The presentation is open to investors, analysts, media, and the public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
conferences
-
News

Merck to Participate in the Leerink Partners Global Biopharma Conference 2024

Rhea-AI Summary
Merck (MRK) to present at Leerink Partners Global Biopharma Conference 2024. Dr. Marjorie Green to discuss oncology developments. Live webcast available for investors and the public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
conferences
-
News

Merck to Participate in the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
Merck (NYSE: MRK) announces Joseph Romanelli's participation in a fireside chat at the TD Cowen 44th Annual Health Care Conference on March 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences
News

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Rhea-AI Summary
Merck (MRK) receives a positive opinion for KEYTRUDA in treating resectable non-small cell lung cancer in Europe based on the Phase 3 KEYNOTE-671 trial results, showing significant improvements in overall survival and event-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
News

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Rhea-AI Summary
Merck's KEYTRUDA plus chemotherapy shows significant improvement in endometrial carcinoma treatment, with FDA accepting sBLA for priority review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
News

Merck Animal Health to Acquire Elanco’s Aqua Business

Rhea-AI Summary
Merck Animal Health, a division of Merck & Co., Inc., is set to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, expanding its aqua portfolio with innovative products and technology solutions. The acquisition includes aqua manufacturing facilities, a research facility, and a portfolio of medicines, vaccines, and supplements for aquatic species. The deal is expected to be completed by mid-year 2024, subject to regulatory approvals and customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
acquisition
News

Elanco Announces Sale of Aqua Business for $1.3 Billion

Rhea-AI Summary
Elanco Animal Health Incorporated (NYSE: ELAN) announced the sale of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, reinforcing its focus on pet health and livestock sustainability. The transaction will enable Elanco to accelerate debt paydown by $1.05B to $1.1B, with net debt to adjusted EBITDA expected in the high-3x to low-4x range by the end of 2025. The aqua business generated an estimated $175 million in revenue and approximately $92 million in adjusted EBITDA in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
-
News

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

Rhea-AI Summary
Merck (MRK) announced its fourth-quarter and full-year sales for 2023, reflecting sustained growth across oncology and vaccines. The worldwide sales for the fourth quarter were $14.6 billion, showing a 6% increase from the fourth quarter of 2022. For the full year, the sales were $60.1 billion, an increase of 1% from 2022. KEYTRUDA sales grew by 19% to $25.0 billion, and GARDASIL/GARDASIL 9 sales grew by 29% to $8.9 billion. However, LAGEVRIO sales declined by 75% to $1.4 billion. Merck also obtained FDA priority review of biologics license applications for V116, an investigational pneumococcal conjugate vaccine, and Patritumab Deruxtecan. The company initiated more than 20 phase 3 study starts and augmented its pipeline through acquisitions and collaboration agreements. The full-year 2024 financial outlook anticipates worldwide sales to be between $62.7 billion and $64.2 billion, with non-GAAP EPS expected to be between $8.44 and $8.59.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
earnings
-
News

The Wall Street Journal Names Merck Among Top 10 Best-Managed Companies

Rhea-AI Summary
Our company, MRK, has been recognized for its strong performance and leadership, ranking No. 10 on The Wall Street Journal's list of the 250 best-managed publicly traded U.S. companies in 2023. The company advanced 78 places from the previous year, showcasing its strategic focus, innovation, and unwavering commitment to saving and improving lives. MRK also secured the No. 1 spot on Newsweek's 2024 list of America's Most Responsible Companies, highlighting its dedication to corporate citizenship and responsible operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
News

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

Rhea-AI Summary
Merck (MRK) announced positive results from the Phase 3 KEYNOTE-564 trial, demonstrating a 38% improvement in overall survival (OS) with KEYTRUDA compared to placebo in patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following surgery. The OS rate at 48 months was 91.2% for KEYTRUDA patients compared to 86.0% for placebo patients. The trial also met its primary endpoint of disease-free survival (DFS) by reducing the risk of disease recurrence or death by 32%. The safety profile of KEYTRUDA was consistent with previous studies, with treatment-related adverse events occurring in 79.1% of KEYTRUDA patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Merck & Co. (MRK)?

The current stock price of Merck & Co. (MRK) is $96.63 as of January 23, 2025.

What is the market cap of Merck & Co. (MRK)?

The market cap of Merck & Co. (MRK) is approximately 251.9B.

What are the main therapeutic areas Merck focuses on?

Merck focuses on several therapeutic areas including cardiometabolic diseases, cancer, and infections. They also have a significant vaccine business and an animal health division.

What is Merck for Mothers?

Merck for Mothers is Merck’s global initiative dedicated to improving maternal health. The program has reached over 30 million women with initiatives that promote safe, high-quality care during pregnancy and childbirth.

What are some of Merck’s key products in oncology?

Merck's oncology portfolio includes KEYTRUDA, an immunotherapy used to treat various cancers, including melanoma. KEYTRUDA has shown significant benefits when used in combination with other therapies.

How significant is Merck’s vaccine business?

Merck has a substantial vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their vaccines portfolio is a major contributor to their public health impact.

Where is Merck headquartered?

Merck is headquartered in Rahway, New Jersey, USA.

What percentage of Merck’s sales comes from the United States?

Approximately half of Merck's sales are generated in the United States.

What is Merck's approach to research and development?

Merck invests heavily in research and development with over 2,250 ongoing clinical trials. Their approach focuses on innovative treatments and combination regimens to address complex health challenges.

What recent achievements has Merck announced?

Merck recently surpassed its goal of reaching 25 million women with its maternal health initiative, Merck for Mothers, by reaching over 30 million women. Additionally, they have reported promising results from clinical trials involving KEYTRUDA.

Does Merck collaborate with other companies for research?

Yes, Merck is actively involved in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

What is the historical origin of Merck & Co., Inc.?

Merck & Co., Inc. originated from the Merck Group, which was founded in Germany in 1668. The American arm, now an independent company, was established to serve the United States and Canada.
Stock MRK logo
Merck & Co., Inc.

NYSE:MRK

MRK Rankings

#34 Ranked by Market Cap
#961 Ranked by Dividends

MRK Stock Data

251.88B
2.53B
0.06%
79.42%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH